

Table S1. Correlation of RT-qPCR results and biopsy variables.

| | RT-qPCR FGFR4 | | RT-qPCR FXR1 | |
|--------------------------------|---------------|--------------|--------------|----------|
| | r | p | r | p |
| Degree of steatosis | -0.642 * | 0.033 | 0.241 | 0.475 |
| Percentage of steatosis | -0.542 | 0.132 | 0.376 | 0.319 |
| Baloonoid degeneration | -0.228 | 0.501 | -0.355 | 0.284 |
| Degree of lobular inflammation | 0.072 | 0.832 | -0.550 | 0.079 |
| Portal inflammation | -0.231 | 0.495 | -0.115 | 0.736 |
| Interphase inflammation | -0.671 * | 0.024 | 0.149 | 0.662 |
| Activity score | -0.445 | 0.170 | -0.308 | 0.357 |
| Degree of fibrosis | -0.323 | 0.333 | -0.323 | 0.333 |

Table S1 provides the correlation values between RT-qPCR FGFR4 and RT-qPCR FXR1 with the different histological parameters evaluated. Correlation coefficients: Spearman's rho. * Correlation is significant at the 0.05 level (bilateral).

Table S2. Baseline and month follow-up results of laboratory tests.

| | Baseline | 1 Month | 3 Months | 6 Months | p |
|----------------------------|------------------------|------------------------|------------------------|------------------------|--------------|
| Total bilirubin (mg/dL) | 0.81 (0.58–1.52) | 0.76 (0.50–1.3275) | 0.71 (0.54–0.91) | 0.77 (0.52–0.99) | 0.915 |
| Direct bilirubin (mg/dL) | 0.12 (0.10–0.84) | 0.17 (0.10–0.31) | 0.10 (0.10–0.14) | 0.10 (0.10–0.15) | 0.292 |
| Indirect bilirubin (mg/dL) | 0.68 (0.47–0.97) | 0.66 (0.38–1.00) | 0.61 (0.40–0.77) | 0.60 (0.40–0.86) | 0.706 |
| ALT (U/L) | 36.00 (18.50–51.75) | 27.00 (18.50–48.00) | 22.00 (18.50–29.00) | 19.00 (16.00–39.00) | 0.843 |
| AST (U/L) | 29 (16.25–34.25) | 28.00 (19.00–39.00) | 23.00 (18.50–27.50) | 22.00 (20.00–28.00) | 0.763 |
| GGT (U/L) | 28.50 (14.00–131.00) | 35.00 (28.50–57.45) | 17.00 (12.00–27.50) | 14.00 (13.00–39.00) | 0.009 |
| FA (U/L) | 70.00 (50.00–101.75) | 73.50 (57.00–87.00) | 62.00 (57.50–83.50) | 68.00 (62.00–70.00) | 0.753 |
| Albumin (g/dL) | 3.92 (3.72–4.21) | 4.14 (3.82–4.40) | 3.97 (3.80–4.15) | 4.01 (3.86–4.20) | 0.457 |
| Cholesterol (mg/dL) | 174.10 (146.25–191.00) | 186.70 (156.70–221.80) | 177.35 (161.85–210.42) | 173.00 (145.00–214.00) | 0.172 |
| LDL cholesterol (mg/dL) | 111.50 (87.25–128.00) | 116.00 (95.00–147.90) | 115.00 (92.50–138.50) | 109.00 (79.00–136.00) | 0.067 |
| Triglycerides (mg/dL) | 94.71 (76.88–127.04) | 129.00 (75.36–232.62) | 106.67 (90.06–115.83) | 101.94 (57.43–132.00) | 0.346 |
| HDL cholesterol (mg/dL) | 39.10 (36.25–48.65) | 42.10 (35.50–49.35) | 45.15 (38.90–56.52) | 53.70 (38.00–61.70) | 0.594 |
| Glucose (mg/dL) | 100.80 (85.82–120.15) | 95.35 (91.75–97.85) | 95.20 (90.22–105.05) | 89.50 (85.90–101.00) | 0.619 |
| HbA1c (%) | 5.50 (5.25–5.75) | 5.40 (5.15–5.60) | 5.30 (5.10–5.70) | 5.30 (5.00–5.60) | 0.340 |
| Insulin (mU/L) | 7.60 (4.90–11.60) | 7.60 (6.10–18.95) | 9.20 (5.65–12.35) | 8.20 (3.20–12.00) | 0.910 |
| HOMA-IR | 2.10 (0.70–2.60) | 2.10 (1.39–3.74) | 1.41 (0.56–2.44) | 0.37 (0.38–2.32) | 0.071 |

Table S2 provides a summary of the variation in biochemical variables during the follow-up periods. Medians, interquartile range. Friedman test, significance level is 0.050.